Ercan Müldür

Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial

Paul G. Richardson, Albert Oriol, Meral Beksaç et al. · The Lancet Oncology · 2019 · 385 citations · Full text

Medicine, Hematology, Pharmacotherapy +11

Prevalence of iron deficiency across different tumors and its association with poor performance status, disease status and anemia

Heinz Ludwig, Ercan Müldür, Georg Endler et al. · Annals of Oncology · 2013 · 260 citations · Full text

Medicine, Hematology, Oncology +16

Efficacy of the combination of bortezomib and dexamethasone in systemic AL amyloidosis

Wolfgang Lamm, Wolfgang Willenbacher, Alois Lang et al. · Annals of Hematology · 2010 · 63 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +8

Lenalidomide and dexamethasone for acute light chain-induced renal failure: a phase II study

Heinz Ludwig, Elisabeth Rauch, Thomas Kuehr et al. · Haematologica · 2014 · 29 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +11

Lupus anticoagulant and thrombosis in splenic marginal zone lymphoma

Johanna Gebhart, Klaus Lechner, Cathrin Skrabs et al. · Thrombosis Research · 2014 · 25 citations

Medicine, Hematology, Immunology +13